Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FRLN

Freeline Therapeutics (FRLN) Stock Price, News & Analysis

Freeline Therapeutics logo

About Freeline Therapeutics Stock (NASDAQ:FRLN)

Advanced Chart

Key Stats

Today's Range
$6.48
$6.48
50-Day Range
$6.43
$6.49
52-Week Range
$2.11
$8.74
Volume
N/A
Average Volume
12,055 shs
Market Capitalization
$28.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FRLN Stock News Headlines

Gold buying hits 4-year high
The perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an epic bull rally in gold. JP Morgan and Goldman Sachs have a price target of $4,000. My research tells me gold could surpass $5,000 in the coming months. Folks using a very specific gold strategy since the 80s could have made more than 60 TIMES their money. Today, you can take advantage of a similar setup for around $10
Acquisition of Freeline by Syncona Becomes Effective
Acquisition of Freeline by Syncona Becomes Effective
Freeline Therapeutics Shareholders Approve Acquisition by Syncona
Freeline Shareholders Approve Acquisition by Syncona
Freeline Therapeutics Holdings plc (FRLN)
See More Headlines

FRLN Stock Analysis - Frequently Asked Questions

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($12.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($15.20) by $2.30.

Shares of Freeline Therapeutics reverse split on the morning of Friday, May 12th 2023.The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Freeline Therapeutics (FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Jabil (JBL), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/09/2021
Today
7/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:FRLN
Fax
N/A
Employees
152
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.97 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$12.07 per share
Price / Book
0.54

Miscellaneous

Free Float
4,259,000
Market Cap
$28.12 million
Optionable
Not Optionable
Beta
0.66
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:FRLN) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners